Dose Insider / Glossary / Mazdutide

MazdutideWhat it is and what the GLORY-1 trial showed

Updated November 20, 2026 · 3 min read · GLORY-1 (NEJM 2025), DailyMed

Mazdutide is a weekly injection from Innovent Biologics that activates two receptors, those for GLP-1 and for glucagon.

−14.01%Mazdutide 6 mg, weight change by week 48
Weight change by week 48GLORY-1, Chinese adults, % of weightMazdutide 6 mg−14.01%Mazdutide 4 mg−11.00%Placebo+0.30%Weight change by week 48GLORY-1, Chinese adults, % of weightMazdutide 6 mg−14.01%Mazdutide 4 mg−11.00%Placebo+0.30%

49.5% on 6 mg lost at least 15% of their weight, against 2.0% on placebo.

On this page

In GLORY-1, a 48-week phase 3 trial in China, adults with obesity or overweight lost 11.00% of their weight on 4 mg and 14.01% on 6 mg, while weight on placebo rose by 0.3%.1 We found no label for it on DailyMed, the U.S. database of drug labels, on November 20, 2026.2

What it is

The GLORY-1 report describes mazdutide as a glucagon-like peptide-1 and glucagon receptor dual agonist.1 It belongs to the same family as survodutide: drugs that pair the GLP-1 receptor with the glucagon receptor, rather than with the GIP receptor as tirzepatide does.3,4 Like the approved GLP-1 medicines it is injected under the skin once a week.1

The GLORY-1 trial

GLORY-1 enrolled 610 adults aged 18 to 75 in China. They qualified with a body mass index of at least 28, or 24 to under 28 with at least one weight-related condition, lower thresholds than the 30, or 27 with a condition, used in the Wegovy and Zepbound trials. At the start they weighed 87.2 kg on average, with a body mass index of 31.1. They took mazdutide 4 mg or 6 mg, or placebo, once a week for 48 weeks.1

The authors report benefits on all the heart and metabolic measures they had planned to check. The trial was funded by Innovent Biologics.1

The main results were set at week 32, not week 48, and were counted for everyone as assigned, whether or not they stopped the drug early or started another weight treatment. That cautious way of counting makes the figures closer to what a person might expect in real use than counts that include only people who stayed on the drug.1

Side effects

The most frequent adverse events were in the stomach and gut and mostly mild to moderate. Few people stopped because of them: 1.5% on 4 mg, 0.5% on 6 mg and 1.0% on placebo.1 Our page on nausea on a GLP-1 covers what helps with the most common one.

Next to other medicines

GLORY-1's numbers are hard to set beside American trials. Its participants were lighter, at 87.2 kg against about 105 kg in the Wegovy and Zepbound label trials, and the trial was shorter.1,5 Weight on placebo did not fall at all, while in the American trials people on placebo lost 2% to 3%, likely helped by lifestyle programs that differ between trials.5 For reference, Wegovy 2.4 mg lowered weight by 14.9% over 68 weeks and Zepbound 15 mg by 20.9% over 72 weeks, in their own trials.5

Survodutide, the other GLP-1 and glucagon drug, lowered weight by up to 14.9% over 46 weeks in a phase 2 trial in 12 countries.3 No trial has compared the two directly in the sources we read.

Where it stands

Mazdutide was tested here in Chinese adults, and its trial program is run by a Chinese company. Without a U.S. label, it is not available as a prescription medicine in the United States, and any product sold online under its name is not one that FDA has reviewed.2,6

Sources

  1. Ji L, Jiang H, Bi Y, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1). N Engl J Med 2025;392:2215-2225. Funded by Innovent Biologics. doi:10.1056/NEJMoa2411528
  2. DailyMed, U.S. National Library of Medicine. Search for "mazdutide", no results; read November 20, 2026. dailymed.nlm.nih.gov
  3. le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024;12:162-173. doi:10.1016/S2213-8587(23)00356-X
  4. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; section 12.1. accessdata.fda.gov
  5. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026, section 14; and ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026, section 14. U.S. Food and Drug Administration. accessdata.fda.gov
  6. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov

Related analyses

Log any GLP-1 medicine you take and see your doses, weight and symptoms together.

Open Dose Insider